Informations générales (source: ClinicalTrials.gov)
ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (ConTTRibute)
Observational
Alnylam Pharmaceuticals (Voir sur ClinicalTrials)
novembre 2020
septembre 2030
05 avril 2025
The purpose of this study is to:
- Describe epidemiological and clinical characteristics, natural history and
real-world clinical management of ATTR amyloidosis patients
- Characterize the safety and effectiveness of patisiran and vutrisiran as part of
routine clinical practice in the real-world clinical setting
- Describe disease emergence/progression in pre-symptomatic carriers of a known
disease-causing transthyretin (TTR) variant
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Clinical Trial Site - Bordeaux - France | Contact (sur clinicalTrials) | ||||
| Clinical Trial Site - Bron - France | Contact (sur clinicalTrials) | ||||
| Clinical Trial Site - Créteil - France | Contact (sur clinicalTrials) | ||||
| Clinical Trial Site - Le Kremlin-Bicêtre - France | Contact (sur clinicalTrials) | ||||
| Clinical Trial Site - Marseille - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for
the cohort of pre-symptomatic carriers
- Germany Only: Patients must be treated per the summary of product characteristics
(SmPC) for any approved treatment for ATTR amyloidosis
- Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for
the cohort of pre-symptomatic carriers
- Germany Only: Patients must be treated per the summary of product characteristics
(SmPC) for any approved treatment for ATTR amyloidosis
- Current enrollment in a clinical trial for any investigational agent